The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo
Identifieur interne : 001A10 ( Main/Exploration ); précédent : 001A09; suivant : 001A11The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo
Auteurs : Moussa B. H. Youdim [Israël] ; A. Wadia [États-Unis] ; W. Tatton [États-Unis] ; Marta Weinstock [Israël]Source :
- Annals of the New York Academy of SciencesNEUROPROTECTIVE AGENTS: FIFTH INTERNATIONAL CONFERENCE [ 0077-8923 ] ; 2001-06.
English descriptors
- KwdEn :
Abstract
Abstract: The antiapoptotic and neuroprotective activity of irreversible monoamine oxidase (MAO) B inhibitor, rasagiline [r(+)‐N‐propargyl‐1‐aminioindan], its S‐isomer (TVP1022) and TV 3219, a novel anti‐Alzheimer cholinesterase‐MAO inhibitor drug derived from rasagiline were examined in PC12 cells cultures and in vivo. We found that these drugs have potent antiapoptotic and neuroprotective activities in response to serum and NGF withdrawal in partially neuronally differentiated PC12 cells and prevent the fall in mitochondrial membrane potential, the first step in cell death. Closed head injury studies in mice have shown that both rasagiline and TVP1022 are neuroprotective. All these compounds possess a propargyl moiety, which normally is responsible for irreversible inactivation of MAO, as is seen with rasagiline. However, neither TVP1022 nor TV3219 are MAO inhibitors, both share the antiapoptotic and neuroprotective actions of rasagiline, indicating that MAO inhibition is not a prerequisite for neuroprotection and that the propargyl moiety exhibits intrinsic neuroprotective pharmacological activity that requires identification.
Url:
DOI: 10.1111/j.1749-6632.2001.tb03656.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo</title><author><name sortKey="Youdim, Moussa B H" sort="Youdim, Moussa B H" uniqKey="Youdim M" first="Moussa B. H." last="Youdim">Moussa B. H. Youdim</name></author><author><name sortKey="Wadia, A" sort="Wadia, A" uniqKey="Wadia A" first="A." last="Wadia">A. Wadia</name></author><author><name sortKey="Tatton, W" sort="Tatton, W" uniqKey="Tatton W" first="W." last="Tatton">W. Tatton</name></author><author><name sortKey="Weinstock, Marta" sort="Weinstock, Marta" uniqKey="Weinstock M" first="Marta" last="Weinstock">Marta Weinstock</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:75E4B6602AF3BDCA81DC35FD34E356C538FDE14A</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1111/j.1749-6632.2001.tb03656.x</idno><idno type="url">https://api.istex.fr/document/75E4B6602AF3BDCA81DC35FD34E356C538FDE14A/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002979</idno><idno type="wicri:Area/Main/Curation">002626</idno><idno type="wicri:Area/Main/Exploration">001A10</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo</title><author><name sortKey="Youdim, Moussa B H" sort="Youdim, Moussa B H" uniqKey="Youdim M" first="Moussa B. H." last="Youdim">Moussa B. H. Youdim</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Technion‐Faculty of Medicine, Eve Topf and National Parkinson Foundation Centers, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Wadia, A" sort="Wadia, A" uniqKey="Wadia A" first="A." last="Wadia">A. Wadia</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mount Sinai School of Medicine, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Tatton, W" sort="Tatton, W" uniqKey="Tatton W" first="W." last="Tatton">W. Tatton</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mount Sinai School of Medicine, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Weinstock, Marta" sort="Weinstock, Marta" uniqKey="Weinstock M" first="Marta" last="Weinstock">Marta Weinstock</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Hebrew University, Department of Pharmacology, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the New York Academy of SciencesNEUROPROTECTIVE AGENTS: FIFTH INTERNATIONAL CONFERENCE</title><idno type="ISSN">0077-8923</idno><idno type="eISSN">1749-6632</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2001-06">2001-06</date><biblScope unit="volume">939</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="450">450</biblScope><biblScope unit="page" to="458">458</biblScope></imprint><idno type="ISSN">0077-8923</idno></series><idno type="istex">75E4B6602AF3BDCA81DC35FD34E356C538FDE14A</idno><idno type="DOI">10.1111/j.1749-6632.2001.tb03656.x</idno><idno type="ArticleID">NYAS450</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0077-8923</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bcl‐2</term><term>Cholinesterase inhibitors</term><term>Closed head injury</term><term>Monoamine oxidase inhibitor</term><term>Neuroprotection</term><term>Propargylamine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The antiapoptotic and neuroprotective activity of irreversible monoamine oxidase (MAO) B inhibitor, rasagiline [r(+)‐N‐propargyl‐1‐aminioindan], its S‐isomer (TVP1022) and TV 3219, a novel anti‐Alzheimer cholinesterase‐MAO inhibitor drug derived from rasagiline were examined in PC12 cells cultures and in vivo. We found that these drugs have potent antiapoptotic and neuroprotective activities in response to serum and NGF withdrawal in partially neuronally differentiated PC12 cells and prevent the fall in mitochondrial membrane potential, the first step in cell death. Closed head injury studies in mice have shown that both rasagiline and TVP1022 are neuroprotective. All these compounds possess a propargyl moiety, which normally is responsible for irreversible inactivation of MAO, as is seen with rasagiline. However, neither TVP1022 nor TV3219 are MAO inhibitors, both share the antiapoptotic and neuroprotective actions of rasagiline, indicating that MAO inhibition is not a prerequisite for neuroprotection and that the propargyl moiety exhibits intrinsic neuroprotective pharmacological activity that requires identification.</div></front></TEI><affiliations><list><country><li>Israël</li><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="Israël"><noRegion><name sortKey="Youdim, Moussa B H" sort="Youdim, Moussa B H" uniqKey="Youdim M" first="Moussa B. H." last="Youdim">Moussa B. H. Youdim</name></noRegion><name sortKey="Weinstock, Marta" sort="Weinstock, Marta" uniqKey="Weinstock M" first="Marta" last="Weinstock">Marta Weinstock</name></country><country name="États-Unis"><region name="État de New York"><name sortKey="Wadia, A" sort="Wadia, A" uniqKey="Wadia A" first="A." last="Wadia">A. Wadia</name></region><name sortKey="Tatton, W" sort="Tatton, W" uniqKey="Tatton W" first="W." last="Tatton">W. Tatton</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A10 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A10 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:75E4B6602AF3BDCA81DC35FD34E356C538FDE14A
|texte= The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo
}}
| This area was generated with Dilib version V0.6.23. |  |